NAFLDObesity, MorbidComorbidities and Coexisting Conditions
Investigational drug(s) / intervention(s)
To propose diagnostic tests for liver diseases before surgical decisions.
To propose diagnostic tests for liver diseases before surgical decisions.: Observational although patients are candidates for metabolic surgery.
Study summary
The investigators seek to analyze the samples provided by patients with obesity-associated fatty liver disease at the multi-omics level and to integrate the results with clinical information, genotypic variants, and factors influencing inter-organ crosstalk. The main aim is to improve the interpretation of fatty liver disease associated with obesity and diabetes by developing predictive models built with algorithms from artificial intelligence. The challenge is to decipher the flow of information by exploring contributing factors, proximate causes of regulatory defects, and maladaptive responses that may promote therapeutic approaches.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Body mass index greater or equal to 40 kg/m\^2.
* Body mass index between 35 and 40 kg/m\^2 with high-risk comorbidities (diagnosis or treatment for hypertension, dyslipidemia, or type 2 diabetes mellitus).
* Positive psychiatric evaluation.
* Age greater or equal to 18 years old.
Exclusion Criteria:
* Legal or illegal drug consumption, including alcohol.
* Diagnosis of Hepatitis.
* Current cancer diagnosis or treatment.
* Clinical or analytical evidence of severe illness.
* Clinical or analytical evidence of chronic or acute inflammation.
* Clinical or analytical evidence of infectious diseases.
* Clinical or analytical evidence of terminal illness.
Primary outcome measure(s)
Weight change — 1 to 10 years The effect of bariatric surgery on adiposity outcomes.
Type 2 diabetes mellitus incidence — 1 to 10 years The effect of bariatric surgery on metabolic outcomes.
Hypertension incidence — 1 to 10 years The effect of bariatric surgery on metabolic outcomes.
Chronic liver diseases incidence — 1 to 10 years The usefulness of imaging techniques on metabolic outcomes.
Dyslipidemia incidence — 1 to 10 years The effect of bariatric surgery on metabolic outcomes.
Trial sites (1)
Facility
City
Region
Status
Hospital Universitari Sant Joan
Reus
Tarragona
Recruiting
More Institut Investigacio Sanitaria Pere Virgili trials in Spain
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
